Eye Bank Association of America’s Post

🐁 Today's JAX Poster Presentations topics at AACR from 1:30-5 p.m., PT, include: • Mouse models advancing cancer research • The mouse models of human cancer database (MMHCdb) • Modeling individual variability in CD19 CAR-T therapy: An in vivo study with PBMC-humanized mice • Accelerated intra-clonal transcriptomic diversification of hematopoietic stem cells during aging fuels leukemia evolution • Spatial proteomics of lung adenocarcinoma mouse models with divergent propensities for metastasis • Spatial immunology landscapes that correlate with survival in triple negative breast cancer https://lnkd.in/exe9h3kU

How does the phase 3 ADRIATIC trial change the standard of care for LS-SCLC? In this #ASCO24 video interview, David R. Spigel, MD, of Sarah Cannon Research Institute, explains what clinicians should know about the study and its implications. Watch now: https://buff.ly/45BH15p #lcsm #SCLC

Following #Immuno2024, you want to learn more about how you can accelerate your immuno-oncology drug discovery with Oncofactory's embryonic xenograft models? Don’t hesitate to contact us at 📧contact@oncofactory.com #lifescience #oncology #CRO #partnering #drugdevelopment #3Rs #NAM #PDXmodel #immunooncology #IO

The launch webinars for our four new CRACK IT Challenges are taking place this week. More details, including the expertise we are seeking, is provided below. Register now through our events calendar: https://lnkd.in/eFQQxJZf Challenge 44 – SensOoChip Tuesday 5 September 2023, 14.00 – 15.15 (BST)   Increasing the reproducibility and predictive power of organ-on-chips through multiparametric real-time monitoring and data modelling. Seeking experts in sensor engineering, in vitro liver and heart organ-on-a-chip (OoC) models or computational approaches. Challenge 45 – CrossDART Wednesday 6 September 2023, 10.00 – 11.15 (BST) Multi species in vitro developmental toxicity testing. Seeking experts in developing in vitro models for developmental toxicity testing. Challenge 46 – FET4Thyroid Wednesday 6 September 2023, 14.00 – 15.15 (BST) A Fish Eleutheroembryo Test for Thyroid Activity. Seeking experts in fish embryo assays to detect endocrine disrupting chemicals. Challenge 47 – aTRACKtive Thursday 7 September 2023, 14.00 – 15.15 (BST) Improved in vivo identification system for real-time, early-life individualised tracking and behavioural and welfare analysis in mice.  Seeking those with experience in approaches that could be applied to identify and track individual mice shortly after birth.

Today we shine a spotlight on Lake Macquarie Private Hospital (LMPH) Clinical Trials Unit, a pivotal site in our network of 20 clinical trial sites nationwide. Managed and led by Hollie Ritchie, this unit drives research across diverse therapeutic areas including oncology, cardiology, neurology, and orthopaedics. Read about one of the current trials conducted at LMPH, the BRCA-P Trial, an international breast cancer prevention trial testing the effectiveness of a drug called ‘Denosumab’ to decrease or prevent the risk of developing breast cancer in women who carry a BRCA1 gene mutation.   If you’re interested in being a part of clinical trials at LMPH or need more information, please reach out to the team at ClinicalTrialsUnit.LMP@ramsayhealth.com.au #ramsaayhealthcare #clinicaltrials #LMPH #peoplecaringforpeople #research #researchatramsay #ramsayresearch https://lnkd.in/gdD_K_wE

📣 Call for abstracts! Deadline 9 September 2023! Are you working on anything related to cancer antigen Wilms' tumor 1 (WT1)? Then, do not forget to submit an abstract for the upcoming 10th International conference on WT1 in Human Neoplasia, which will take place in Antwerp on 26-28 October 2023. Regulations: Abstracts in English should include in following order: - the title in bold and in 12-point characters - the name of the author(s); the name of the presenting author should be underlined and he/she should be the person submitting the abstract - the affiliation(s) of the author(s) - empty single line - text of the abstract typed with 11-point characters and with single spacing the text can be continuous or can contain different paragraphs File format: - the full abstract, including all the elements cited above, should not exceed 1 page in the final document that is uploaded in the abstract submission module - the uploaded document should be in pdf format Schedule and deadlines: The deadline for abstract submission is 9th September 2023. Notifications will be made at the latest by 6th October 2023.

A few months ago, my wife Lenny, a non-smoker, received the devastating news of her metastatic lung cancer diagnosis. On top of that, it turns out to be a very rare, incurable variant, ROS1+. ROS1+ lung cancer is an aggressive form of the disease that predominantly affects non-smokers, like my wife. The urgency to find effective treatments and therapies is paramount, and research is the beacon of hope. More information about this cancer, patients and research, can be found on https://lnkd.in/egEddhs8 . Despite the challenges my wife faces, she remains steadfast in her determination to fight this disease, not just for herself, but for her 7yo daughter and countless others affected by this rare form of cancer. You can read about her experiences on her blog site, www.kankervriendinnen.nl . Lenny's only hope is the further development of inhibitor medication. As November is lung cancer awareness month, I would like to ask you to donate to the ROS1+ foundation to enable further research, and also, please share this post for more visibility. Lenny's unwavering spirit and her plea for help echo in every word she speaks. She is not only seeking treatment but also advocating for increased research funding to provide hope and better prospects for individuals battling ROS1+ lung cancer. Please donate: https://lnkd.in/eMN7gAYv Your donation, no matter the size, will contribute to the advancements in ROS1+ lung cancer research, bringing it one step closer to a cure and becoming a chronic disease instead of an incurable cancer variant.

Check our recent publication. #USMIRC

our case report is live @ OMCR.

BREAKING: Utah set to legalize non-FDA approved placental cell therapies. “A health care provider whose scope of practice includes the use of stem cell therapy may perform a stem cell therapy that is not approved by the United States Food and Drug Administration.” A state-by-state adoption of medical marijuana legalization has overcome federal roadblocks to help millions of Americans. A state-by-state adoption of locally regulated regenerative medicine may do the same for healthcare. This is huge. https://lnkd.in/esjV_FNv